GlassScriptPhysician profile
Ronald Gaines
NPI 1477539096
$2,911.12
in general payments reported to CMS, 2019-2025
27 companies · $542 in 2025
The $542 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $93.26 · 2021: $291 · 2022: $591 · 2023: $728 · 2024: $551 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,821.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $340.69 | 2022-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $302.43 | 2021-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $291.27 | 2022-2023 | Acthar |
| Calliditas Therapeutics US INC. | $264.98 | 2023-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $259.89 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $242.01 | 2019-2025 | Jynarque, Voyxact |
| Novartis Pharmaceuticals Corporation | $201.81 | 2023-2025 | |
| Vifor Pharma, INC. | $167.50 | 2019-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $117.53 | 2022-2024 | |
| Aurinia Pharma U.S., INC. | $108.88 | 2021-2024 | Lupkynis |
| Akebia Therapeutics INC | $94.88 | 2019-2025 | Vafseo |
| Nxstage Medical, INC. | $85.48 | 2023 | Liberty Select Cycler, Nxstage System One |
| Glaxosmithkline, LLC. | $64.15 | 2021-2023 | Benlysta |
| Opko Pharmaceuticals, LLC | $60.98 | 2021 | |
| Ardelyx, INC. | $44.69 | 2024-2025 | Ibsrela |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $39.08 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $34.30 | 2023 | Ultomiris |
| Fresenius USA Marketing, INC. | $28.59 | 2019-2021 | |
| Mozarc Medical US LLC | $23.26 | 2025 | Palindrome |
| Cycle Pharmaceuticals INC | $19.98 | 2025 | Venxxiva |
| Shield Therapeutics INC | $18.51 | 2025 | |
| Daiichi Sankyo INC. | $18.37 | 2020 | |
| Ani Pharmaceuticals, INC. | $18.03 | 2025 | Purified Cortrophin Gel |
| Apellis Pharmaceuticals, INC. | $16.86 | 2025 | Empaveli |
| Lilly USA, LLC | $16.56 | 2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.85 | 2025 | Jardiance |
| Novo Nordisk INC | $14.56 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Gaines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.